Related Experiment Video
Updated: Nov 25, 2025
10:48
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
9.8K
Perampanel Add-on to Standard Radiochemotherapy in vivo Promotes Neuroprotection in a Rodent F98 Glioma Model
Falko Lange1,2, Jens Hartung1, Clara Liebelt1
1Oscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
Frontiers in Neuroscience
|December 17, 2020
Summary
Perampanel (PER) did not reduce glioblastoma growth but effectively controlled seizures associated with the tumor. PER also protected healthy brain tissue in rats receiving radiochemotherapy.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Glioblastoma disrupts glutamate signaling, potentially causing tumor progression and seizures.
- AMPA receptor antagonists are being investigated for glioma treatment.
Purpose of the Study:
- To evaluate perampanel (PER) as an adjuvant therapy to radiochemotherapy (RCT) for glioblastoma.
- To assess PER's impact on tumor growth and associated epileptic seizures.
Main Methods:
- Orthotopic F98 glioma rat model used.
- Perampanel (15 mg/kg) administered as adjuvant to RCT.
- Video-EEG, field potential recordings, tumor quantification, survival analysis, and immunohistology employed.
Main Results:
- F98 glioma induced an epileptiform phenotype in rats.
- RCT reduced tumor size and improved survival.
- Perampanel did not affect tumor progression.
- Both PER and RCT abolished tumor-associated seizures.
- PER preserved glutamatergic network activity in healthy peritumoral tissue.
Conclusions:
- Perampanel is an effective anticonvulsant for glioma-associated epilepsy.
- Perampanel may protect surrounding healthy tissue when used with RCT.
- Perampanel did not demonstrate efficacy in reducing glioblastoma growth or improving survival.
